Abstract:Abstract Introduction Hypertrophic and keloid scarring are considered as major determinants for long-term outcomes and quality of life for burn survivors. Keloid development is predicated on prolonged local inflammation and altered glucose metabolism. Owing to its tumor-like dependence on glucose, we hypothesized that keloids would display the bioenergetics of cancer cells; namely, increased glucose uptake via Glut1 and upregulation of key glycolytic enzymes. Furthermore, burn patients who develop keloids potentially demonstrate early evidence of the aforementioned features compared to non-keloid patients. Therefore, elevated Glut1 expression could serve as a marker for keloid development in burn patients. Methods We enrolled 27 control burn patients with 39% ± 4% total body surface area (TBSA) burns. The keloid burn group included 9 burn patients with 47% ± 9% TBSA burns. Skin was obtained for histology, gene and protein expression at 0–17 days post-burn. Results Keloids have higher Glut1 expression compared to normal and burn skin (7.72 vs. 0.15, p< 0.001; 7.72 vs. 2.35, p< 0.05). Keloids also exhibit enhanced expression of critical glycolytic enzymes compared to burn skin at 7–10 days post-burn (HK2: 4.14 vs. 2.36, p< 0.001; PFK1: 6.51 vs. 3.83, p< 0.001; PFK2: 5.35 vs. 1.27, p< 0.001; PDK1: 5.50 vs. 4.31, p< 0.05; PKM2: 7.58 vs. 2.98, p< 0.001). A Glut1 time-course analysis in burn skin from non-keloid patients indicated a significant elevation at 7–10 days post-burn compared to normal skin (3.22 vs. 0.20, p< 0.01). Skin from keloid burn patients prior to development of keloids demonstrate higher Glut1 expression compared to skin from non-keloid controls when matched by days post-burn (40.5 vs. 0.58 at 0–2 days, p< 0.05). Conclusions Patients who develop post-burn keloids exhibit early risk factors prior to the development of keloids (e.g. elevated skin Glut1). Keloids have an augmented reliance on glycolysis compared to burn skin. Therefore, early identification and targeting glycolysis in susceptible patients is key. Applicability of Research to Practice Upregulation of glycolytic enzymes and transporters such as Glut1 may serve as keloid predictive markers. Identification of at-risk patients allows for a tailored treatment regimen that targets dysregulated glycolysis in these patients. Pharmaceutical agents like shikonin suppress multiple glycolytic steps, serving as an effective means to interfere with the proliferative capacity of keloids. Potentially, local shikonin administration could serve as a therapy in select patients exhibiting keloid risk factors.

Enhanced bioenergetic cellular activity with metabolic switch to aerobic glycolysis in Keloid and Folliculitis Keloidalis Nuchae

Metabolic Reprogramming in Keloid Fibroblasts: Aerobic Glycolysis and a Novel Therapeutic Strategy.

Mitochondrial Dysfunction and Morphological Abnormality in Keloid Fibroblasts

Exosomes Released by Melanocytes Modulate Fibroblasts to Promote Keloid Formation:A Pilot Study

Altered glucose metabolism and cell function in keloid fibroblasts under hypoxia

53 Regulation of Glycolysis and the Warburg Effect in Keloids

Keloidal Pathophysiology: Current Notions.

[Mitochondrial Dysfunctions of Keloid Fibroblasts and It' S Effects on Cell Metabolic Functions].

Comprehensive Modular Analyses of Scar Subtypes Illuminate Underlying Molecular Mechanisms and Potential Therapeutic Targets.

Deciphering the single-cell transcriptome network in keloids with intra-lesional injection of triamcinolone acetonide combined with 5-fluorouracil

Revealing the pathogenesis of keloids based on the status: Active vs inactive

Metabolism, fibrosis, and apoptosis: The effect of lipids and their derivatives on keloid formation

Characterization of the skin keloid microenvironment

Studies of Transforming Growth Factors Beta 1-3 and Their Receptors I and II in Fibroblast of Keloids and Hypertrophic Scars.

Novel needle‐type electrocoagulation and combination pharmacotherapy: Basic and clinical studies on efficacy and safety in treating keloids

Profibrotic Subsets of SPP1 + Macrophages and POSTN + Fibroblasts Contribute to Fibrotic Scarring in Acne Keloidalis

Keloid disorder: Fibroblast differentiation and gene expression profile in fibrotic skin diseases

Keloid Disorder: Genetic Basis, Gene Expression Profiles, and Immunological Modulation of the Fibrotic Processes in the Skin

Comprehensive Insights into Keloid Pathogenesis and Advanced Therapeutic Strategies

Natural killer cell dysfunction drives keloid pathogenesis

Increased Melanin Induces Aberrant Keratinocyte−melanocyte−basal−fibroblast Cell Communication and Fibrogenesis by Inducing Iron Overload and Ferroptosis Resistance in Keloids